{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:45:47Z","timestamp":1771379147556,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beha.2020.101151","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T20:46:39Z","timestamp":1579725999000},"page":"101151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Modern treatments and future directions for newly diagnosed multiple myeloma patients"],"prefix":"10.1016","volume":"33","author":[{"given":"Sydney X.","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.beha.2020.101151_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.beha.2020.101151_bib2","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging System for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2020.101151_bib3","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2017.053","article-title":"Non-secretory myeloma: ready for a new definition?","volume":"9","author":"Corso","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"10.1016\/j.beha.2020.101151_bib4","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.beha.2020.101151_bib5","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.beha.2020.101151_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2020.101151_bib7","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.beha.2020.101151_bib8","article-title":"A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET\/CT, 18F-NaF-PET\/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients","volume":"6","author":"Dyrberg","year":"2017","journal-title":"Acta Radiol Open"},{"issue":"12","key":"10.1016\/j.beha.2020.101151_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.beha.2020.101151_bib10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/14737159.2019.1627877","article-title":"ClonoSEQ assay for the detection of lymphoid malignancies","volume":"19","author":"Monter","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"18","key":"10.1016\/j.beha.2020.101151_bib11","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"485","key":"10.1016\/j.beha.2020.101151_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.beha.2020.101151_bib13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/leu.2015.341","article-title":"Gene signature combinations improve prognostic stratification of multiple myeloma patients","volume":"30","author":"Chng","year":"2016","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.beha.2020.101151_bib14","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-16-0867","article-title":"Gene expression profiles in myeloma: ready for the real world?","volume":"22","author":"Szalat","year":"2016","journal-title":"Clin Canc Res"},{"issue":"5","key":"10.1016\/j.beha.2020.101151_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2020.101151_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2020.101151_bib17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2020.101151_bib18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2020.101151_bib19","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2020.101151_bib20","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2020.101151_bib21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"9383","key":"10.1016\/j.beha.2020.101151_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.beha.2020.101151_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10068","key":"10.1016\/j.beha.2020.101151_bib24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beha.2020.101151_bib25","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10192","key":"10.1016\/j.beha.2020.101151_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.beha.2020.101151_bib27","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2020.101151_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2020.101151_bib29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101151_bib30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2019-123401","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in alcyone","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2020.101151_bib31","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.beha.2020.101151_bib32","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2020.101151_bib33","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjh.12946","article-title":"Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis","volume":"166","author":"Leiba","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.beha.2020.101151_bib34","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101151_bib35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.13296","article-title":"Phase Ib\/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma","volume":"169","author":"Mikhael","year":"2015","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.beha.2020.101151_bib36","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: from biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101151_bib37","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"10.1016\/j.beha.2020.101151_bib38","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2020.101151_bib39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.beha.2020.101151_bib40","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.beha.2020.101151_bib41","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2020.101151_bib42","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.beha.2020.101151_bib43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: bringing the bench to the bedside","volume":"12","author":"Mailankody","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2020.101151_bib44","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bmt.2016.24","article-title":"MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.beha.2020.101151_bib45","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101151_bib46","first-page":"397","article-title":"Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02\/HO95 study","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101151_bib47","first-page":"435","article-title":"Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101151_bib48","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial","volume":"37","author":"Gay","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101151_bib49","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2018-99-114956","article-title":"A quadruplet regimen comprising carfilzomib, cyclophosphamide, lenalidomide, dexamethasone (KCRD) Vs an immunomodulatory agent containing triplet (CTD\/CRD) induction therapy prior to autologous stem cell transplant: results of the myeloma XI study","volume":"132","author":"Jackson","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101151_bib50","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood-2019-121694","article-title":"Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (Ixa Dara dex) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients; results of the interim efficacy analysis of the phase II HOVON 143 study","volume":"134","author":"Stege","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101151_bib51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2018-151","volume":"132","author":"Voorhees","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101151_bib52","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood-2019-123465","article-title":"Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): Griffin study update","volume":"134","author":"Voorhees","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101151_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2018-99-111065","article-title":"Phase 2 trial of ixazomib, lenalidomide, dexamethasone and daratumumab in patients with newly diagnosed multiple myeloma","volume":"132","author":"Kumar","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101151_bib54","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood-2019-131476","article-title":"Phase 2 trial of daratumumab, ixazomib, lenalidomide and modified dose dexamethasone in patients with newly diagnosed multiple myeloma","volume":"134","author":"Kapoor","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101151_bib55","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2019-126378","article-title":"Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a clinical and correlative phase 2 study","volume":"134","author":"Landgren","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101151_bib56","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2019-123170","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:44Z","timestamp":1761498344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521692620300128"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101151","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern treatments and future directions for newly diagnosed multiple myeloma patients","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101151"}}